Tag: hirschler
-
‘New day’ in lung cancer as Merck drug shines, works with chemo
By Ben Hirschler COPENHAGEN (Reuters) – Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy. As a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths…
-
‘New day’ in lung cancer as Merck drug shines, works with chemo
By Ben Hirschler COPENHAGEN (Reuters) – Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy. As a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths…
-
Roche lung cancer drug success adds to pressure on Bristol
By Ben Hirschler COPENHAGEN (Reuters) – Lung cancer patients on Roche’s immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study, pressuring Bristol-Myers Squibb’s dominant position in the field. The trial involved second-line patients, who have already used chemotherapy, and it found the Roche drug worked even…
-
Roche lung cancer drug success adds to pressure on Bristol
By Ben Hirschler COPENHAGEN (Reuters) – Lung cancer patients on Roche’s immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study, pressuring Bristol-Myers Squibb’s dominant position in the field. The trial involved second-line patients, who have already used chemotherapy, and it found the Roche drug worked even…
-
Medics dash to rural Haiti as cholera kills 13 in Matthew’s wake
By Makini Brice and Joseph Guyler Delva PORT SALUT, Haiti/PORT-AU-PRINCE (Reuters) – Cholera has killed at least 13 people in southwest Haiti in the wake of Hurricane Matthew, officials said on Saturday, as government teams fanned out across the hard-hit southwestern tip of the country to repair treatment centers and reach the epicenter of one…
-
AstraZeneca buys most of Acerta for $4 billion to add cancer drug
By Ben Hirschler LONDON (Reuters) – AstraZeneca said on Thursday it had agreed to buy 55 percent stake of privately held biotech firm Acerta Pharma for $4 billion to give it access to a new kind of drug for fighting blood cancers. AstraZeneca will pay $2.5 billion upfront, with a further $1.5 billion paid either…
-
AstraZeneca buys most of Acerta for $4 billion to add cancer drug
By Ben Hirschler LONDON (Reuters) – AstraZeneca said on Thursday it had agreed to buy 55 percent stake of privately held biotech firm Acerta Pharma for $4 billion to give it access to a new kind of drug for fighting blood cancers. AstraZeneca will pay $2.5 billion upfront, with a further $1.5 billion paid either…
-
High schools listening to scientists, letting teens sleep
SEATTLE (AP) — More school districts around the U.S. are heeding the advice of scientists who have long said that expecting teens to show up to class before 8 a.m. isn't good for their health or their report cards.
-
BTG gets triple dose of good news on new products
LONDON (Reuters) – Specialist medicine company BTG received a triple dose of good news on Monday as U.S. regulators approved two new treatments and a clinical trial of a novel lung device produced positive results. U.S. green lights for Vistogard and Lumi, for chemotherapy overdoses and tumors, and the success of PneumRx coils in severe…